Form 4 for EW Edwards Lifesciences
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-07 · accession 0001225208-22-006816 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-10 | 2022-05-08+ | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | M - OptEx | $12.25 | +19.3K | 71.9K | +37% | +$236.7K |
| DM | 2022-05-10 | 2022-05-07+ | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | F - Tax | $100.52 | -8,216 | 59.3K | -12% | -$825.9K |
| D | 2022-05-10 | 2022-05-09 | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | S - Sale+OE | $98.71 | -6,725 | 64.3K | -9% | -$663.8K |
| DM | 2022-05-10 | 2022-05-08+ | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | M - OptEx | $0.00 | -19.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-09 | M | A | 6,725 | $35.20 | 71,028.78 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-08 | F | D | 7,612 | $100.52 | 64,303.78 | D | — | — | |
| 3 | Common | Common Stock | 2022-05-08 | M | A | 12,600 | $0.00 | 71,915.78 | D | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 4 | Common | Common Stock | 2022-05-07 | F | D | 604 | $100.52 | 59,315.78 | D | — | — | |
| 5 | Common | Common Stock | 2022-05-09 | S | D | 6,725 | $98.71 | 64,303.78 | D | — | — | |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-09 | M | D | 6,725 | $0.00 | 73,975 | D | $35.20 · 2017-05-12 to 2023-05-11 | 6,725 Common Stock | |
| 7 | Derivative | Performance Rights | 2022-05-08 | M | D | 12,600 | $0.00 | 0 | D | — · 2022-05-08 to 2026-05-07 | 12,600 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |